Jose Rubio Mosquera, MD
Rheumatology · Birmingham, ALNPI 1174907984
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,585 of the $7,569 with a category attached, or 87.0%. 7 manufacturers reported payments, led by AbbVie at 51.5% of the total. 2025 is the largest year on record at $7,203, more than ten times the $191 reported in 2019. That places this record below the midpoint for rheumatology clinicians in AL, where the typical reported total is $8,965.
Across 29 payments — averaging $260.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$3K
- E.r. Squibb & Sons, L.L.C.$140
- Aurinia Pharma U.S., Inc.$125
- GSK$118
- Lilly USA, LLC$17
- plus $15 from 1 others
Across 66 payments — averaging $12,360 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$321K
- Genentech, Inc.$192K
- Novartis$145K
- AstraZeneca$48K
- Amgen$33K
- UCB SA$30K
- plus $47K from 3 others
What the payments were for
- Consulting fees$6,58587%
- Travel & lodging$3715%
- Food & beverage$6138%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $3,900 |
| AstraZeneca | 7 | $3,254 |
| E.r. Squibb & Sons, L.L.C. | 16 | $140 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| GSK | 1 | $118 |
| Lilly USA, LLC | 2 | $17 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,569 in reported general payments places this provider in the 45th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BenlystaBelimumab | 381 | $1,747,267 |
| LupkynisVoclosporin | 19 | $281,476 |
| SaphneloAnifrolumab-Fnia | 33 | $160,269 |
| RinvoqUpadacitinib | 25 | $151,016 |
| Orencia ClickjectAbatacept | 26 | $142,970 |
| ThalomidThalidomide | 14 | $77,980 |
| Actemra ActpenTocilizumab | 12 | $52,975 |
| Bosentan | 14 | $51,076 |
| Hydroxychloroquine Sulfate | 419 | $23,211 |
| PlaquenilHydroxychloroquine Sulfate | 12 | $10,103 |
| Mycophenolate Mofetil | 73 | $7,544 |
| MethotrexateMethotrexate Sodium | 111 | $5,998 |
| Cevimeline Hcl | 28 | $5,931 |
| Leflunomide | 56 | $4,802 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $3,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $118 | $1,747,267381 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $125 | $281,47619 claims |
| AstraZenecaSaphnelo | $3,254 | $160,26933 claims |
| AbbVieRinvoq | $3,900 | $151,01625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Birmingham
- Jeffrey CurtisBirmingham$612K
- David McLainBirmingham$588K
- Kenneth SaagBirmingham$143K
- Maria DanilaBirmingham$46K
- Matthew MullenBirmingham$38K
- Angelo Gaffo LlontopBirmingham$36K
- Greg EudyBirmingham$33K
- John MorganBirmingham$11K
- Kurt BlakeBirmingham$7K
- Amanda AlexanderBirmingham$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.